Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved OTC

18

Investigational

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Prostaglandin G/H synthase 1

18

Prostaglandin G/H synthase 2

18

Adenosine A2a receptor

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

18

Phase II

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1899

18

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Headache

18

Myocardial infarction

18

Pain

18

Stroke

18

Chronic obstructive pulmonary disease

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

19

Preventing

18

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

18

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Bayer

18

Pfizer

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

19

All Match

Any Match

Exclude Selected

Exclude Selected

INN Stem

Chemical substance(-ine)

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

19

FDA UNII

19

PUBCHEM

19

EPA CompTox

18

SMS_ID

14

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

BLOOD AND BLOOD FORMING ORGANS

3

NERVOUS SYSTEM

3

ALIMENTARY TRACT AND METABOLISM

1

CARDIOVASCULAR SYSTEM

1

MUSCULO-SKELETAL SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANALGESICS

3

ANTITHROMBOTIC AGENTS

3

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

1

BETA BLOCKING AGENTS

1

LIPID MODIFYING AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTITHROMBOTIC AGENTS

3

OTHER ANALGESICS AND ANTIPYRETICS

3

ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION

1

BETA BLOCKING AGENTS, OTHER COMBINATIONS

1

LIPID MODIFYING AGENTS, COMBINATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Platelet aggregation inhibitors excl. heparin

3

Salicylic acid and derivatives

3

Antiinflammatory/antirheumatic agents in combination with corticosteroids

1

Beta blocking agents, other combinations

1

HMG CoA reductase inhibitors, other combinations

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

17

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 19 results

First page disabled
Previous page disabled
1
Next page
Next page

ASPIRIN ALUMINUM

E33TS05V6B

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1899

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Prostaglandin G/H synthase 2

Prostaglandin G/H synthase 1

Conditions:

Myocardial infarction

Aspirin is a nonsteroidal anti-inflammatory drug. Aspirin is unique in this class of drugs because it irreversibly inhibits both COX-1 and COX-2 activity by acetylating a serine residue (Ser529 and Ser516, respectively) positioned in the arachidonic ...

acid-binding channel, thus inhibiting the synthesis of prostaglandins and reducing the inflammatory response. The drug is used either alone or in combination with other compounds for the treatment of pain, headache, as well as for reducing the risk of stroke and heart attacks in patients with brain ischemia and cardiovascular diseases.

UK-432097

8L3OAJ1R5A

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Adenosine A2a receptor

Conditions:

Chronic obstructive pulmonary disease

UK-432097 is a selective adenosine A2a agonist which was in development with Pfizer as an inhaled treatment for asthma and chronic obstructive pulmonary disease. UK-432097 had been in phase II clinical trials by Pfizer for the treatment of chronic ob...

structive pulmonary disease (COPD). However, this study was terminated prematurely due to futility based on results of interim analysis.

DIHYDROXYALUMINUM ASPIRIN

20D04M9OLN

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1899

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Prostaglandin G/H synthase 2

Prostaglandin G/H synthase 1

Conditions:

Myocardial infarction

Aspirin is a nonsteroidal anti-inflammatory drug. Aspirin is unique in this class of drugs because it irreversibly inhibits both COX-1 and COX-2 activity by acetylating a serine residue (Ser529 and Ser516, respectively) positioned in the arachidonic ...

acid-binding channel, thus inhibiting the synthesis of prostaglandins and reducing the inflammatory response. The drug is used either alone or in combination with other compounds for the treatment of pain, headache, as well as for reducing the risk of stroke and heart attacks in patients with brain ischemia and cardiovascular diseases.

ALUMINUM ACETYLSALICYLATE

ED7L5F608H

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1899

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Prostaglandin G/H synthase 2

Prostaglandin G/H synthase 1

Conditions:

Myocardial infarction

Aspirin is a nonsteroidal anti-inflammatory drug. Aspirin is unique in this class of drugs because it irreversibly inhibits both COX-1 and COX-2 activity by acetylating a serine residue (Ser529 and Ser516, respectively) positioned in the arachidonic ...

acid-binding channel, thus inhibiting the synthesis of prostaglandins and reducing the inflammatory response. The drug is used either alone or in combination with other compounds for the treatment of pain, headache, as well as for reducing the risk of stroke and heart attacks in patients with brain ischemia and cardiovascular diseases.

Aspirin Trelamine Hydrochloride

J0TQX5LV1L

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1899

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Prostaglandin G/H synthase 2

Prostaglandin G/H synthase 1

Conditions:

Myocardial infarction

Aspirin is a nonsteroidal anti-inflammatory drug. Aspirin is unique in this class of drugs because it irreversibly inhibits both COX-1 and COX-2 activity by acetylating a serine residue (Ser529 and Ser516, respectively) positioned in the arachidonic ...

acid-binding channel, thus inhibiting the synthesis of prostaglandins and reducing the inflammatory response. The drug is used either alone or in combination with other compounds for the treatment of pain, headache, as well as for reducing the risk of stroke and heart attacks in patients with brain ischemia and cardiovascular diseases.

ASPIRIN ARGININE

4FES8WRA60

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1899

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Prostaglandin G/H synthase 2

Prostaglandin G/H synthase 1

Conditions:

Myocardial infarction

Aspirin is a nonsteroidal anti-inflammatory drug. Aspirin is unique in this class of drugs because it irreversibly inhibits both COX-1 and COX-2 activity by acetylating a serine residue (Ser529 and Ser516, respectively) positioned in the arachidonic ...

acid-binding channel, thus inhibiting the synthesis of prostaglandins and reducing the inflammatory response. The drug is used either alone or in combination with other compounds for the treatment of pain, headache, as well as for reducing the risk of stroke and heart attacks in patients with brain ischemia and cardiovascular diseases.

CARBASPIRIN

73J0P7720Y

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1899

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Prostaglandin G/H synthase 2

Prostaglandin G/H synthase 1

Conditions:

Myocardial infarction

Aspirin is a nonsteroidal anti-inflammatory drug. Aspirin is unique in this class of drugs because it irreversibly inhibits both COX-1 and COX-2 activity by acetylating a serine residue (Ser529 and Ser516, respectively) positioned in the arachidonic ...

acid-binding channel, thus inhibiting the synthesis of prostaglandins and reducing the inflammatory response. The drug is used either alone or in combination with other compounds for the treatment of pain, headache, as well as for reducing the risk of stroke and heart attacks in patients with brain ischemia and cardiovascular diseases.

ALOXIPRIN

6QT214X4XU

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1899

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Prostaglandin G/H synthase 2

Prostaglandin G/H synthase 1

Conditions:

Myocardial infarction

Aspirin is a nonsteroidal anti-inflammatory drug. Aspirin is unique in this class of drugs because it irreversibly inhibits both COX-1 and COX-2 activity by acetylating a serine residue (Ser529 and Ser516, respectively) positioned in the arachidonic ...

acid-binding channel, thus inhibiting the synthesis of prostaglandins and reducing the inflammatory response. The drug is used either alone or in combination with other compounds for the treatment of pain, headache, as well as for reducing the risk of stroke and heart attacks in patients with brain ischemia and cardiovascular diseases.

ASPIRIN DL-LYSINE

2JJ274J145

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1899

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Prostaglandin G/H synthase 2

Prostaglandin G/H synthase 1

Conditions:

Myocardial infarction

Aspirin is a nonsteroidal anti-inflammatory drug. Aspirin is unique in this class of drugs because it irreversibly inhibits both COX-1 and COX-2 activity by acetylating a serine residue (Ser529 and Ser516, respectively) positioned in the arachidonic ...

acid-binding channel, thus inhibiting the synthesis of prostaglandins and reducing the inflammatory response. The drug is used either alone or in combination with other compounds for the treatment of pain, headache, as well as for reducing the risk of stroke and heart attacks in patients with brain ischemia and cardiovascular diseases.

ASPIRIN COPPER

5DR11472UI

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1899

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Prostaglandin G/H synthase 2

Prostaglandin G/H synthase 1

Conditions:

Myocardial infarction

Aspirin is a nonsteroidal anti-inflammatory drug. Aspirin is unique in this class of drugs because it irreversibly inhibits both COX-1 and COX-2 activity by acetylating a serine residue (Ser529 and Ser516, respectively) positioned in the arachidonic ...

acid-binding channel, thus inhibiting the synthesis of prostaglandins and reducing the inflammatory response. The drug is used either alone or in combination with other compounds for the treatment of pain, headache, as well as for reducing the risk of stroke and heart attacks in patients with brain ischemia and cardiovascular diseases.

Showing 1 - 10 of 19 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1